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a b s t r a c t
Various cellular perturbations implicated in the pathophysiology of human diseases, including cardio-
vascular and neurodegenerative diseases, diabetes mellitus, obesity, and liver diseases, can alter en-
doplasmic reticulum (ER) function and lead to the abnormal accumulation of misfolded proteins. This
situation conﬁgures the so-called ER stress, a form of intracellular stress that occurs whenever the
protein-folding capacity of the ER is overwhelmed. Reduction in blood ﬂow as a result of atherosclerotic
coronary artery disease causes tissue hypoxia, a condition that induces protein misfolding and ER stress.
In addition, ER stress has an important role in cardiac hypertrophy mainly in the transition to heart
failure (HF). ER transmembrane sensors detect the accumulation of unfolded proteins and activate
transcriptional and translational pathways that deal with unfolded and misfolded proteins, known as the
unfolded protein response (UPR). Once the UPR fails to control the level of unfolded and misfolded
proteins in the ER, ER-initiated apoptotic signaling is induced. Furthermore, there is considerable evi-
dence that implicates the presence of oxidative stress and subsequent related cellular damage as an
initial cause of injury to the myocardium after ischemia/reperfusion (I/R) and in cardiac hypertrophy
secondary to pressure overload. Oxidative stress is counterbalanced by complex antioxidant defense
systems regulated by a series of multiple pathways, including the UPR, to ensure that the response to
oxidants is adequate. Nuclear factor-E2-related factor (Nrf2) is an emerging regulator of cellular re-
sistance to oxidants; Nrf2 is strictly interrelated with the UPR sensor called pancreatic endoplasmic
reticulum kinase. A series of studies has shown that interventions against ER stress and Nrf2 activation
reduce myocardial infarct size and cardiac hypertrophy in the transition to HF in animals exposed to I/R
injury and pressure overload, respectively. Finally, recent data showed that Nrf2/antioxidant-response
element pathway activation may be of importance also in ischemic preconditioning, a phenomenon in
which the heart is subjected to one or more episodes of nonlethal myocardial I/R before the sustained
coronary artery occlusion.
& 2015 Elsevier Inc. All rights reserved.
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Introduction
Although from 2000 to 2010 death rates attributable to all
cardiovascular diseases (CVD) signiﬁcantly declined, in 2010 CVD
still accounted for 31.9% of all deaths (more than 2 million people)
in the United States [1]. In particular coronary artery disease (CAD)
still determined about one of every six deaths, with almost
400,000 Americans dead owing to this disease [1].
Atherosclerosis is the leading cause of cerebrovascular and CV
diseases, which together account for a third of all deaths in Wes-
tern countries [2,3]. Multiple risk factors, including hypertension,
smoking, diabetes mellitus, dyslipidemia, obesity, and a sedentary
lifestyle contribute to the initiation and progression of athero-
sclerosis [4]. Compromised blood ﬂow and cellular perfusion lead
to ischemia that causes deleterious effects on the organs in
question: examples of acute ischemia include stroke, myocardial
infarction, and organ transplantation. The primary goal in ische-
mia is therefore to restore blood ﬂow as soon as possible, keeping
in mind, however, that a rapid reestablishment of blood ﬂow can
cause oxidative stress-related organ damage, i.e., the so-called
ischemia/reperfusion (I/R) injury [5]. Animal and human studies
[6–9] have revealed that oxygen deprivation in the heart causes
endoplasmic reticulum (ER) stress of myocytes, i.e., ER accumula-
tion of unfolded and misfolded proteins, a situation that can lead
to cell apoptosis if not counteracted by the unfolded protein re-
sponse (UPR), a collection of actions designed to mitigate or
eliminate ER stress and regain homeostasis. In addition, it has
been reported that ischemic stress through various mechanisms
can activate nuclear factor-E2-related factor (Nrf2) [10–12], which
is involved in increasing the levels of endogenous antioxidants
[13], attenuating apoptosis [14], and increasing mitochondrial
biogenesis [15]. In addition, the UPR and Nrf2 have also been re-
ported to be activated in cardiac hypertrophy and heart failure
(HF) [16,17], a major and increasing public health problem espe-
cially in industrialized societies with aging populations.
The purpose of this article is to examine and discuss the current
evidence for a cardioprotective role of UPR and Nrf2 in CAD and in
left-ventricular hypertrophy (LVH) in the transition to HF.
ER stress and the UPR
It is known that the majority of protein precursors, i.e., un-
folded polypeptides, fold in the ER of eukaryotic cells [reviewed in
18]. In general, cells adjust the protein-folding capacity of the ER
according to their requirements, and the proteins that have been
correctly folded exit the ER to their ﬁnal destination. It was in-
itially reported that manipulations that artiﬁcially increase the
load of unfolded ER proteins activate the expression of genes that
encode ER-resident chaperones [19]. It was then shown that var-
ious cellular perturbations implicated in the pathophysiology of
human diseases, including CVD, neurodegenerative diseases, dia-
betes mellitus, obesity, and liver diseases [20], can alter ER func-
tion and lead to the abnormal accumulation of misfolded proteins.
This situation conﬁgures the so-called ER stress, a form of in-
tracellular stress that occurs whenever the protein-folding capa-
city of the ER is overwhelmed [18]. This accumulation signals in-
cipient problems and activates transcriptional and translational
pathways that deal with unfolded and misfolded proteins, known
as the UPR [18]. Only recently have ER stress and UPR been con-
sidered potential contributors to CVD [21,22].
Three main ER transmembrane stress sensors initiate UPR: in-
ositol-requiring enzyme 1 (IRE-1), pancreatic endoplasmic re-
ticulum kinase (PERK), and activating transcription factor 6 (ATF6)
[18,23,24]. All three sensors are maintained in an inactive state
through the interaction of their N-terminus with the glucose-
regulated protein 78 kDa (GRP78) [18].
IRE-1 is activated by the presence of misfolded proteins in the
ER lumen [reviewed in 18 and 25]. The binding of misfolded
proteins to IRE-1 causes a conformational change of IRE-1 that
activates RNase activity. Depending on the degree of ER stress the
sequelae of IRE-1 activation may be different: in the presence of
low levels of ER stress it catalyzes the splicing of the mRNA en-
coding X-box-binding protein 1 (XBP1), removing a 26-nucleotide
intron, which changes the reading frame. Active XBP1 enters the
nucleus and increases the transcription of chaperones and other
UPR-related proteins that enhance the ER-associated degradation
(ERAD) of misfolded proteins. IRE-1 also degrades certain mRNAs
through regulated IRE-1-dependent decay, so reducing the protein
load to the ER. If otherwise ER stress is sustained and prolonged,
IRE-1 can also be involved in activation of inﬂammation and
apoptosis [25–30].
PERK inactivates eukaryotic translation initiation factor (eIF)
2α, which reduces protein translation, so allowing the cell to fold
the proteins already present in the ER. ATF4 mRNA escapes
translational suppression induced by PERK, because it possesses
an internal ribosome entry site sequence in its 5′ untranslated
region [31]. In the presence of low-grade ER stress, ATF4 induces
the expression of C/EBP homologous protein (CHOP), which at low
concentrations favors the induction of several genes central in cell
survival and the UPR [32]. However, if ER stress is prolonged, PERK
greatly increases CHOP, thus blocking the expression of the anti-
apoptotic BCL family member protein Bcl2, favoring cell death
[33]. In addition, PERK phosphorylates Kelch-like ECH-associated
protein 1 (Keap1), thereby freeing Nrf2 from its inhibitor and al-
lowing its nuclear import for the expression of antioxidant and
detoxiﬁcation enzymes [34].
ATF6, including two isoforms, ATF6α (90 kDa) and ATF6β
(110 kDa), is another transmembrane sensor protein that becomes
a powerful transcription factor upon regulated intramembrane
proteolysis-speciﬁc cleavage in the Golgi complex [18]. After
cleavage, the cytosolic N-domain of ATF6 translocates into the
nucleus where it induces the expression of many UPR-related
genes, including GRP78, CHOP, and XBP1 [18].
There is a cross talk between ER stress and autophagy, an
evolutionary process by which cellular macromolecules and or-
ganellar components are sequestered within double-membrane
vesicles and delivered to lysosomes for degradation and recycling
of bioenergetic substrates [reviewed in 35]. ER stress can induce
autophagy, through at least two UPR pathways, PERK–eIF2α and
IRE-1 [35,36].
Once the UPR fails to control the level of unfolded and mis-
folded proteins, ER-initiated apoptotic signaling pathways are in-
duced, and in this setting CHOP has been shown to play a key role
[18]. In ER-stressed cells, CHOP has been demonstrated to induce
ER oxidase 1α, which activates inositol triphosphate receptor-
mediated release of calcium into the cytosol and subsequent ac-
tivation of calcium/calmodulin-dependent protein kinase kinase II
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[37–39], which triggers apoptosis through various mechanisms. In
addition, CHOP has also been reported to upregulate the proa-
poptotic proteins Bim- and p53-upregulated modulator of apop-
tosis (PUMA), which induce mitochondrial-dependent apoptosis
[40,41]. Finally, CHOP, through the induction of its transcriptional
target DNA damage-inducible protein 34 (GADD34), blocks the
activity of eIF2α and restores protein translation with ER pertur-
bation and cell death [42].
The Keap1–Nrf2 pathway
Nrf2 belongs to a small family of transcription factors con-
taining a unique basic-leucine-zipper (bZIP) motif, the cap-n-collar
(CNC) family [43,44]. Although three other CNC–bZIP transcription
factors have been reported in mammals, which have been desig-
nated NF-E2 p45, Nrf1, and Nrf3 [reviewed in 44 and 45], Nrf2
reportedly is the main mediator of cellular adaptation to redox
stress [46]. Nrf2 activates a series of enzymes with antioxidant and
detoxifying activity that play a key role in the protection of the
cells against various environmental stresses, such as electrophiles,
reactive oxygen species, and reactive nitrogen species [47]. Ad-
ditionally, Nrf2 controls the transcription of several drug-meta-
bolizing enzymes, transporters, cellular reducing equivalents
(glutathione (GSH) and NADPH), and proteasomes [48].
Domain analysis of Nrf2 has shown that Nrf2 is composed of
seven conserved Nrf2-erythroid cell-derived protein with CNC
homology (Neh) domains [49,50]. The Neh1 domain contains the
bZIP motif, which allows Nrf2 to bind to the antioxidant-response
element (ARE) sequence. In addition, this domain can interact with
E2 ubiquitin-conjugating enzyme to regulate the Nrf2 protein sta-
bility [51]. The Neh2 domain, located in the most N-terminal region,
acts as a negative regulatory domain by binding to the Nrf2 in-
hibitor Keap1 [45]. Keap1 possesses four functional domains: Broad
complex, Tramtrack, and Bric-a-Brac (BTB); intervening region;
double glycine repeat or Kelch repeat (DGR); and C-terminal region
[52]. Under basal or unstressed conditions, Nrf2 remains in an in-
active cytoplasmic form through association with the BTB domain-
containing protein Keap1 [53]. Although it was initially thought that
Nrf2 activation was strictly regulated through the inhibition of
nuclear import, increasing evidence has shown that Nrf2 protein
levels are kept at low levels through proteasome-mediated de-
gradation [54–56]. In general, proteins are targeted to the 26 S
proteasome through the covalent attachment of polyubiquitin
chains. Ubiquitin conjugation is mediated by the sequential activ-
ities of an E1 enzyme, which mediates the ATP-dependent activa-
tion of ubiquitin; an E2 ubiquitin-conjugating enzyme; and an E3
ubiquitin ligase; E2 and E3 coordinate the transfer of ubiquitin to
the substrate protein [57]. Keap1 functions as a substrate adaptor
protein for a Cullin 3 (Cul3)/ring box 1 (Rbx1)-dependent ubiquitin–
protein ligase complex that forms the E3 ligase complex [58]. Via its
N-terminal BTB domain, Keap1 binds to Cul3/Rbx1 and, via its
C-terminal DGR domain, binds to Nrf2, leading to the ubiquitination
and subsequent degradation of Nrf2 through the 26 S proteasome
[59,60]. Under basal conditions, therefore, Nrf2 is rapidly degraded
by the cytosolic Keap1/Cul3/Rbx1 complex. In contrast, under
stressed conditions, the ability of the Cul3–Keap1–E3 ligase to
ubiquitinate Nrf2 is inhibited, allowing Nrf2 to translocate to the
nucleus and initiate the antioxidant response [44,45]. The me-
chanisms by which Nrf2 is released from Keap1 have been actively
investigated. One mechanism proposed is that the cysteine thiol
groups of Keap1 function as sensors for oxidative stress, causing
formation of disulﬁde bonds between cysteines of two Keap1
peptides and leading to conformational changes that render Keap1
unable to bind Nrf2 [61]. Alternatively, dissociation of Nrf2 from
Keap1 has been reported to be caused by protein kinase C-induced
phosphorylation at Nrf2 Ser-40 [62]. It has been reported that these
two mechanisms can work in concert [63]. As for antioxidant de-
fense genes, Nrf2 induces a series of enzymes and molecules in-
volved in (1) catabolism of superoxide and peroxides, such as su-
peroxide dismutase, catalase, peroxiredoxin, and glutathione per-
oxidase; (2) regeneration of oxidized cofactors and proteins,
whereby oxidized GSH is reduced by glutathione reductase, oxi-
dized thioredoxin by thioredoxin reductase, and oxidized peroxir-
edoxin by sulﬁredoxin; and (3) synthesis of reducing factors such as
GSH and NADPH [48]. Finally, Nrf2 induces the expression of several
oxidant-signaling proteins that affect particular cellular functions
such as autophagy [64], inﬂammation [65], inﬂammasome signaling
[66], ER stress and the UPR [67], apoptosis [14], and mitochondrial
biogenesis [15].
There is evidence that persistent accumulation of Nrf2 in the
nucleus is harmful; to avoid accumulation of Nrf2 in the nucleus,
cells contain mechanisms that autoregulate the cellular abundance
of Nrf2 [45,68,69]. As recently reviewed by Niture et al. [45], the
complex Keap1/Cul3/Rbx1 is present not only in the cytosol, but
also in the nucleus, where it degrades Nrf2 and therefore controls
the “switching off” of Nrf2-activated gene expression.
A feedback autoregulatory loop between Keap1 and Nrf2 con-
trols the cellular abundance of Keap1 and Nrf2 [70]: Nrf2 regulates
Keap1 by regulating its transcription, and Keap1 controls Nrf2 by
facilitating its degradation. More recently, it was shown that an-
other autoregulatory loop exists between Nrf2 and Cul3/Rbx1 [71].
Nrf2 controls the transcription of Cul3 and Rbx1 and the Cul3/
Rbx1 complex ubiquitinates and degrades Nrf2. In other words,
there exists cellular homeostasis between Nrf2 and the Keap1/
Cul3/Rbx1 complex. In addition, in the nucleus there are other
Nrf2 negative regulators. In particular it has been reported that all
four Src subfamily members, including Fyn, Src, Yes, and Fgr, fol-
low Nrf2 in the nucleus and phosphorylate Nrf2 Tyr-568, which
leads to nuclear export and ubiquitination/degradation of Nrf2
[68]. Furthermore, there is evidence that the transcription factor
Bach1 is a further negative regulator of Nrf2 because it has been
reported to compete with Nrf2 for binding to the ARE [69]. So in
response to stress, the kinetics of the Nrf2 cycle has two phases: in
the ﬁrst Nrf2 is activated in response to stress and imported in the
nucleus, where it forms heterodimers with its partners and binds
to the ARE; subsequently, the nuclear Keap1/Cul3/Rbx1complex,
Src subfamily members, and Bach1 switch Nrf2 activation off. As
recently reported it is likely that the ﬁrst phase runs in parallel to a
preinduction phase in which the Nrf2 negative regulators are ex-
ported out of the nucleus [45].
In addition to mediating stress-stimulated induction of anti-
oxidant and detoxiﬁcation genes, Nrf2 contributes to adaptation
by modulating intermediary metabolism. In particular, Nrf2 in-
hibits lipogenesis, supports β-oxidation of fatty acids, facilitates
ﬂux through the pentose phosphate pathway, and increases
NADPH regeneration and purine biosynthesis [72].
Cross talk between UPR and Nrf2
Among the various transcription factors that are induced or
repressed by the UPR, Nrf2 has been proposed to play a major role
in regulating the non-antioxidant and antioxidant response trig-
gered by the UPR [reviewed in 73].
Although it is well established that PERK participates in the
regulation of Nrf2 phosphorylation and dissociation from Keap1
[34], the induction of ASK1 is also likely to play a role in this route,
through the TRAF2-mediated kinase action of IRE-1 [74]. Further-
more it has been assessed that there is an interaction between
Nrf2 and the ubiquitin/proteasome system, because Nrf2 has been
shown to directly activate ubiquitin/proteasome genes [73]. In
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particular, recent results indicate that the Nrf2 pathway con-
tributes to the ER stress response by enhancing proteasome-
mediated ERAD [75]. Although Nrf1 is an ER-membrane-settled
transcription factor that possesses many similarities with Nrf2
[73], there is now evidence suggesting that Nrf1 strongly en-
hances, with an afﬁnity even greater than Nrf2, the expression of
proteasomal subunits [76]. Furthermore it has been reported that
Nrf1, but not Nrf2, is likely to induce de novo expression of pro-
teasomal subunits after application of proteasomal inhibitors [77].
So, it has been hypothesized that after ERAD failure to remove
unfolded protein accumulation, Nrf1 may stimulate an alternative
ERAD pathway [78].
Finally it has been recently reported that Hrd1, a downstream
effector of the IRE-1 branch of the UPR, mediates the suppression
of the Nrf2 pathway in liver cirrhosis [79]. In response to ER stress
XBP1 mRNA is spliced by IRE-1 to produce active XBP1, which in
turn induces transcriptional upregulation of Hrd1 [79]. In Wu et
al.‘s paper [79], it is shown that activation of the XBP1–Hrd1 arm
of ER stress causes an enhanced Nrf2 ubiquitylation and de-
gradation of the Nrf2 signaling pathway.
Role of ER stress and Nrf2 in evolving vulnerable athero-
sclerotic plaques
Previous studies on sudden coronary death found that plaque
rupture with subsequent thrombotic occlusion is a central me-
chanism of acute myocardial infarction and sudden coronary death
[80,81]. Rupture-prone or vulnerable plaques are generally char-
acterized by the presence of a high content of inﬂammatory cells
and a large necrotic core covered by a thin ﬁbrous cap, with de-
creased smooth muscle cell (SMC) and extracellular matrix content
[82], the so-called thin-cap ﬁbroatheromata (TCFA). Other com-
mon features of the TCFA include expansive remodeling, large
plaque size, plaque hemorrhage, neovascularization, adventitial
inﬂammation, and “spotty” calciﬁcations [83].
Many studies have shown that apoptotic macrophages accu-
mulate in advanced atherosclerotic plaques [84]. When phago-
cytes cannot adequately remove the apoptotic macrophages (de-
fective efferocytosis), these apoptotic cells become secondarily
necrotic and coalesce over time into a key feature of vulnerable
plaque, the necrotic core [85,86]. The consequence of accelerated
macrophage apoptosis coupled with defective efferocytosis is the
expansion of the necrotic core [85,86], a major feature responsible
for plaque disruption [87].
It has been shown that ER stress may play a crucial role in the
evolvement of atherosclerotic plaque. Initial works by Feng et al.
[88] and then by Zhou and collaborators [89] have shown that
plaque macrophages of chow-fed or Western diet-fed ApoE" /"
mice were characterized by UPR and high expression of CHOP.
Furthermore, Myoishi et al. [90] found a higher expression of
GRP78, GRP94, and CHOP in the macrophages and SMCs of TCFA
and ruptured plaques than in thick-cap human atheroma. In
agreement with these results, we have recently reported [91] that
in the tissue around the necrotic core of carotid plaques there was
an abnormal amount of macrophage-derived apoptotic cells. This
phenomenon was associated with a sustained ER stress with
abundance of CHOP and apoptosis-related gene expression, sug-
gesting that ER stress may promote macrophage apoptosis and
favor the expansion of the necrotic core. In contrast to the in-
creased CHOP and apoptosis-related gene expression, Nrf2 was
very poorly expressed in the macrophages of the tissue around the
necrotic core, whereas it was strongly represented in the cells at
the periphery of the plaque [91].
Evidence also indicates that Nrf2 may play a central role in
stimulating the non-antioxidant response through interrelation
with UPR-gene regulation [73]. In this context, Nrf2 signaling has
been shown to upregulate the expression of the proteasome cat-
alytic subunits in several cell types and to contribute to the ER
stress response by enhancing proteasome-mediated ERAD [75,92].
So far, however, there are no data showing that this mechanism
operates also in macrophages of vulnerable plaques.
Cardioprotective role of the UPR
Evidence indicates that the ER plays a key role in cardiomyo-
cytes for multifunctional organelle support: in fact proper synth-
esis and correct folding of proteins in the ER are extremely im-
portant for the normal function of the heart [93]. Recent studies
indicate that various cellular stresses including hypoxia, I/R,
pressure overload, hypertrophy, and drug-induced insults may
activate ER stress [94]. However, although ER stress and UPR have
been extensively studied in nonmuscle ER, relatively few studies of
ER stress and UPR have been performed in the cardiovascular
context [21].
Ischemic heart disease
There is now a great interest in understanding the mechanisms
that link ER stress signaling to human pathology and in particular
to CAD. Reduction in blood ﬂow as a result of arterial athero-
sclerotic occlusion causes tissue hypoxia and hypoglycemia, two
conditions that have been proposed to induce protein misfolding
and ER stress [93]. In support of this ﬁnding, there are previous
studies showing that cerebral ischemia activates several pathways
of the UPR [95,96]. On the basis of these results in the brain,
several following studies have addressed the role of ER stress in
the myocardium exposed to ischemia or I/R. In this context it has
been reported that many ER stress genes were expressed in mouse
hearts with ischemia-induced myocardial infarction [97]. Thuerauf
et al. [6] reported that IRE-1, by encoding XBP1, increased the
transcription of chaperones and other UPR-related proteins and
enhanced ERAD in infarcted mouse heart and hypoxic-cultured
cardiac myocytes. Furthermore IRE-1 has been implicated in the
activation of autophagy, a prosurvival important defense me-
chanism in cardiac injuries such as hypertrophy and I/R [98]. Vi-
tadello et al. [8] showed that the XBP1- and ATF6-regulated
overexpression of GRP94 reduced the necrosis due to calcium
overload or simulated ischemia in cardiac myocytes. Similarly,
Martindale et al. [99] and Doroudgar et al. [100] demonstrated
that ATF6/XBP1 and therefore GRP94 overexpression protected
mouse hearts and cultured cardiac myocytes from ischemia. Bel-
mont et al. [101] demonstrated that the ATF6-induced over-
expression of Derlin-3, which encodes an important component of
the ERAD machinery, attenuated long-term ER stress in myocytes
and in an in vivo mouse model of myocardial infarction, suggesting
that enhancing elements of the ERAD can protect heart from is-
chemic injury. Severino et al. [9] focused on the molecular me-
chanisms activated during postinfarction remodeling in human
hearts and identiﬁed protein disulﬁde isomerase (PDI), a member
of the UPR, as a key factor of the survival pathway. In fact, they
found that the PDI gene was upregulated in the viable peri-infarct
myocardial region within the ﬁrst days after infarction, and in a
postmortem model, the expression of PDI was inversely correlated
with apoptotic rate and presence of HF. Taken together these re-
sults suggest that the protective role of PDI in human infarcted
hearts is mediated by a reduction in apoptotic rate and by pre-
vention of cardiac remodeling [9]. These ﬁndings support the in-
volvement of the UPR in ischemia and its protective role in pre-
venting ischemia injury in CAD. On the other hand, Terai et al.
[102] demonstrated that simulated hypoxia in neonatal rat
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cardiomyocytes also induced CHOP expression and cleavage of
caspase 12, indicating that ER-initiated apoptotic signaling is in-
volved in cell death after a hypoxic insult. Furthermore Nickson
et al. [103] reported that in primary cultures of rat and mouse
neonatal cardiomyocytes, ER stress increased the expression of
PUMA, a proapoptotic member of the Bcl2 family, and that PUMA
expression inhibition protected ischemic cardiomyocytes from
apoptosis. The results of all these studies are schematically shown
in Fig. 1.
Very recently [104] we set out to determine the expression of
the UPR in peripheral mononuclear cells derived from patients
with stable angina and found that GRP78 and CHOP expression
was signiﬁcantly higher in stable angina patients than in healthy
controls. This augmented expression was correlated with the ab-
normal cellular content of superoxide and hydrogen peroxide
generated by NADPH oxidase (Nox). Although it has been shown
that Nox4-mediated hydrogen peroxide production may be car-
dioprotective through the induction of autophagy [105], it is likely
that it is an excess of oxidative stress that switches from protection
to ER-initiated apoptotic signaling [104].
The results of all these studies show that ischemia-associated
ER stress can cause both cell survival and apoptosis and suggest
that the degree and the length of ischemia may be the dis-
criminating factors between cell survival or death.
LVH and HF
LVH is generally believed to be a compensatory mechanism in
response to stress from neurohumoral activation, hypertension, or
other myocardial injury. The heart initially compensates with an
adaptive enlargement of the myocardium that is characterized by
an increase in the size of cardiac myocytes and whole-organ mass.
However, prolonged LVH is harmful and leads to HF [106,107].
In the past decade, several studies have demonstrated the in-
volvement of ER stress in the transition from compensated LVH to
HF. In cardiac tissue from patients with dilated cardiomyopathy
Okada et al. ﬁrst demonstrated an increased expression of GRP78,
indicating that UPR activation is associated with HF in humans
[108]. In the same paper, the authors also found that mice sub-
jected to transverse aortic constriction (TAC) developed LVH after
1 week and HF after 4 weeks. They also focused on the changes in
UPR activation and ER-initiated apoptosis signaling after TAC: in-
triguingly, although UPR activation was present both in LVH and in
HF, activation of CHOP occurred only in HF [108]. Then to clarify
the mechanism of ER induction by TAC, cardiomyocytes were
treated with angiotensin II (Ang II): the results indicated that Ang
II acts as an ER stress inducer in rat cardiomyocytes; however,
long-term induction of ER stress by Ang II was shown to induce
apoptosis, through CHOP/GADD153 expression [108]. As con-
ﬁrmation of the role of ER stress-mediated apoptosis in HF, an
increased expression of CHOP in myocardial samples from patients
with HF has been demonstrated [109]. The authors also examined
the effect of CHOP gene deletion on ER-mediated apoptosis and HF
dysfunction induced by pressure overload: CHOP-deﬁcient mice
showed less LVH, ﬁbrosis, and cardiac dysfunction compared with
wild-type mice at 4 weeks after TAC, suggesting that CHOP may
also contribute to the development of LVH in the transition to HF
[109]. In this context, it has been reported that CHOP regulates the
expression of GADD34, which inhibits the phosphorylation of
eIF2α [110]; therefore, under CHOP-deﬁcient conditions decreased
expression of GADD34 in pressure-overloaded hearts may lead to
enhanced phosphorylation of eIF2α and decreased protein synth-
esis, thus contributing to the prevention of LVH.
PERK has recently been demonstrated to protect the heart from
pressure-overload-induced congestive HF: in response to chronic
TAC, PERK-knockout mice exhibited decreased ejection fraction,
increased left-ventricular ﬁbrosis, and enhanced cardiomyocyte
apoptosis [111]. The increased CHOP expression also found in
PERK-knockout hearts after TAC conﬁrms that CHOP may con-
tribute to the left-ventricular dysfunction by increasing apoptosis.
In the same paper [111] the authors also observed a signiﬁcant
decline in sarcoplasmic reticulum Ca2þ ATPase (SERCA2a) ex-
pression. SERCA2a is a well-deﬁned regulator of calcium home-
ostasis in cardiomyocytes [112], and ER calcium depletion result-
ing from reduced SERCA2a activity has been shown to induce ER
stress [113]. Because SERCA2a activity is critical for preserving
cardiac function, the dramatic SERCA2a fall in PERK-knockout mice
after TAC is probably an important mechanism for pressure-over-
load-induced congestive HF.
Prostatic androgen-repressed message 1 (PARM-1) protein has
been recently related to LVH and HF in Dahl salt-sensitive rats
[114]. Furthermore, downregulation of PARM-1 expression by
siRNA in cultured cardiomyocytes markedly attenuated the ex-
pression of PERK and ATF6 under ER stress; in contrast, CHOP
induction was markedly augmented by PARM-1 silencing. These
ﬁndings indicate that PARM-1 plays a crucial role in maintaining
PERK and ATF6 expression in the setting of ER stress conditions
Fig. 1. Endoplasmic reticulum stress-dependent responses to ischemia/reperfusion. ER, endoplasmic reticulum; IRE-1, inositol-requiring enzyme 1; PERK, pancreatic en-
doplasmic reticulum kinase; ATF6, activating transcription factor 6; PDI, protein disulﬁde isomerase; XBP1, X-box-binding protein 1; ERAD, endoplasmic reticulum-asso-
ciated degradation; EIF2α, eukaryotic translation initiation factor 2α; ATF4, activating transcription factor 4; GRP94, glucose-regulated protein 94 kDa; Derl3, Derlin-3; CHOP,
C/EBP homologous protein; Bcl2, B-cell lymphoma 2; PUMA, proapoptotic proteins Bim- and p53-upregulated modulator of apoptosis. References are in parentheses.
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and controls cardiomyocyte survival by suppressing CHOP-medi-
ated apoptotic pathways [114].
In conclusion, the animal and human studies performed so far
[115,116] have revealed that UPR and ER-initiated apoptosis are
implicated in the pathophysiology of LVH leading to HF. The initial
effects of ER stress would favor the prosurvival phase of the
pathway and therefore might provide cardiovascular protection.
However, during prolonged stress, cardiomyocytes may exhibit a
relatively compressed time of transition from prosurvival to
proapoptotic phases of ER stress, thus contributing to HF.
Cardioprotective role of Nrf2
Ischemic heart disease
There is considerable evidence that implicates the production
of oxidative stress and subsequent related cellular damage as an
initial cause of injury to the myocardium after ischemia and I/R
injury [117]. During myocardial reperfusion, in fact, the myo-
cardium already damaged by the ischemic insult is further sub-
jected to several abrupt biochemical and metabolic changes, which
compound the injuries generated during the period of myocardial
ischemia [118]. These changes include mitochondrial reenergiza-
tion, oxidative stress, intracellular Ca2þ overload, the restoration
of physiologic pH, and inﬂammation; all these factors interact with
one another to mediate cardiomyocyte death [96]. Oxidative stress
is counterbalanced by complex antioxidant defense systems
regulated by a series of multiple pathways to ensure that the re-
sponse to oxidants is adequate. It has been shown that Nrf2 is an
important factor in controlling both constitutive and inducible
expression of a wide spectrum of antioxidants and phase 2 en-
zymes in cardiomyocytes and is responsible for protecting these
cells against oxidative and electrophilic stress. These ﬁndings also
implicate Nrf2 as an important signaling molecule for myocardial
cytoprotection [119]. In this context, a variety of interventions
against Nrf2 induction have been shown to offer myocardial pro-
tection in animals exposed to ischemia and I/R injury [10,120–
127].
A recently classiﬁed small-molecule effector produced in the
body by the enzyme cystathionine lyase, hydrogen sulﬁde (H2S),
has been reported to provide cardioprotection in various models of
cardiac injury [128]. Calvert et al. [10] found that transgenic mice
with cardiac-restricted overexpression of the H2S-generating en-
zyme cystathione lyase displayed a clear protection against left-
ventricular structural and functional impairment in response to
ischemia-induced heart failure. The cardioprotective effect of H2S
was mostly related to the induction of endogenous antioxidants,
through Nrf2 pathway activation [10].
Ashraﬁan et al. [12] generated fumarate hydratase cardiac-
knockout mice. These fumarate-replete hearts were strongly pro-
tected from ischemia and I/R injury because fumarate potently
increased the expression of ARE-regulated genes, through activa-
tion of Nrf2. In addition they found that exogenous oral fumaric
acid derivatives gave the same cardioprotective effects in non-
transgenic animals experiencing ischemia and I/R [12]. Similar
results were reported by Deng et al. [125], who demonstrated that
α-lipoic acid reduces infarct size and preserves cardiac function in
rat myocardial I/R injury through activation of the Nrf2 pathway.
Although in all these animal studies the activation of the Nrf2/ARE
pathway has shown to reduce myocardial infarction size, so far
there are no studies showing that activation of Nrf2 has a pro-
tective effect on myocardial infarction size in humans.
Nrf2/ARE pathway activation may be of importance also in is-
chemic preconditioning, an endogenous cardioprotective phe-
nomenon; in this experimental setting, myocardial infarct size can
be dramatically reduced by subjecting the heart to one or more
episodes of nonlethal myocardial I/R before the sustained coronary
artery occlusion [129]. Although proof-of-principle studies using
different conditioning strategies in CAD patients undergoing
elective or emergency coronary revascularization have been per-
formed to clarify if ischemic conditioning can improve clinical
outcomes, the results are still contradictory, there being both po-
sitive and negative data [130]. The reasons for the negative ﬁnd-
ings have been mainly attributed to the varying presence of CAD
risk factors, comorbidities, and medications in patient cohorts
[130]. Other limitations of these studies are the limited number of
patients and the use of surrogate rather than clinical outcome
endpoints [108]. Ongoing clinical trials (e.g., CIRCUS, ERICCA, RI-
PHeart) will clarify if ischemic conditioning can improve clinical
outcomes [130].
Very recently Xu et al. [127] found that Nrf2-knockout mice, in
addition to having an increased infarction size in response to I/R,
had a reduced degree of cardiac protection by means of ischemic
preconditioning. In contrast, an elevated Nrf2 protein expression
was observed in heart wild-type mice exposed to ischemic pre-
conditioning [127]. Of course the activation of the Nrf2 pathway
may be only one of the elements that contributes to the intricate
mechanisms involved in cardioprotective preconditioning [re-
viewed in 130] and further studies are needed to clarify if Nrf2 is
deﬁnitely central in explaining the favorable outcomes of pre-
conditioning. Fig. 2 schematically shows some interventions that
through Nrf2/ARE pathway activation induce cardioprotection in
ischemia and I/R.
LVH and HF
It is ﬁrmly established that oxidative stress plays a causative
role in the pathogenesis of CVD, including pathological LVH and HF
[131–135]. Oxidative stress derives from the activation of some
intracellular enzymes such as NADPH oxidase or xanthine oxidase,
uncoupling of nitric oxide synthase, and electron transport and
“leakage” during oxidative phosphorylation in the mitochondria
[136–138].
Oxidative stress has been identiﬁed as a key player in the de-
velopment of cardiac hypertrophy [139], through the activation of
speciﬁc pathways leading to adaptive or maladaptive cardiac re-
modeling processes [140]. In this context, on the other hand, re-
cent studies indicate that the H2O2-generating enzyme Nox4 ex-
erts beneﬁcial cardiac and vascular effects during chronic hemo-
dynamic stress [141,142] through Nrf2 activation [143].
Initially, in in vitro experiments Nrf2/ARE signaling was shown
to play an important role in preventing oxidative cardiac cell in-
jury [144,145]. Then, it was demonstrated that heme oxygenase
(HO)-1 attenuated Ang II-induced cardiac hypertrophy both in
vitro and in vivo [146]. Furthermore, Ndisang and Jadhav [147]
reported that upregulation of HO-1 reduced LVH and extracellular
matrix remodeling in spontaneously hypertensive rats. Similarly,
upregulation of cytoprotective HO-1 through Bach1 deletion in-
hibited TAC-induced LVH [148]. In contrast, Chen et al. [149] de-
monstrated that in transgenic mice overexpressing HO-1, TAC in-
creased the levels of calcineurin compared to wild-type mice, so
worsening the pressure-overload-induced LVH. These results in-
dicate that the role of HO-1 in pressure-overload-induced cardiac
remodeling is still controversial and needs further investigation. At
variance with this negative ﬁnding in transgenic mice over-
expressing HO-1, it was shown that after TAC Nrf2-knockout mice
developed pathological LVH, signiﬁcant myocardial ﬁbrosis and
apoptosis, and overt HF. Overexpression of Nrf2, instead, drasti-
cally inhibited LVH and cardiac ﬁbrosis, suggesting that Nrf2 is a
critical regulator for maintaining the structural and functional
integrity of the heart that is abnormally stressed [150].
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Taken together the results of these studies suggest that acti-
vation of Nrf2 and its correlated ARE genes, by inhibiting oxidative
stress, protects the heart from pressure-overload-induced patho-
logical cardiac hypertrophy, ﬁbrosis, apoptosis, and HF.
The understanding of the mechanisms that upregulate Nrf2
expression has allowed the development of compounds affecting
Nrf2 activation and with the potential to treat CVD. Many Nrf2
activators are natural products and plant-derived phytochemicals
such as sulforaphane, curcumin, resveratrol, allicin, and garlic or-
ganosulfur compounds [151]. Curcumin, for instance, has been
shown to reduce acute doxorubicin-induced cardiomyopathy in
rats [152]. In an Ang II-induced LVH and HF rat model allicin
prevented cardiac remodeling and its progression to HF [153]. In
addition, dietary phytochemical intake was shown to reduce oxi-
dative damage and HF in hypertensive rats [154].
Various synthetic Nrf2 activators have also been synthesized,
such as carbobenzoxy-Leu-Leu-leucinal (MG132), 4-hydro-
xynonenal, α-lipoic acid, hydrogen sulfate, and 17β-estradiol
[122,123,125]. Both sulforaphane and MG132 have been shown to
prevent cardiac LVH, ﬁbrosis, and HF in high blood pressure dia-
betic mice [155,156]. In addition, in a pressure-overload-induced
rodent HF model, treatment with MG132 was reported to at-
tenuate LVH and cardiac ﬁbrosis as well as improving cardiac
function [157,158].
Conclusions
In the past decade several studies have addressed the me-
chanisms involved in heart injury ischemia, I/R, and LVH in the
transition to HF. Although some studies suggest that UPR activa-
tion during heart ischemia, I/R, and LVH in the transition to HF
may contribute to protecting myocytes, there are some others that
support the possibility that UPR may even worsen the myocyte
damage. The reasons underlying these conﬂicting results are
poorly understood; it is possible that similar to other signaling
pathways, the UPR can mediate both protective and damaging
effects in the heart, depending upon the context. With the un-
derstanding that some functions of ER stress are adaptive, whereas
others are maladaptive, it is likely that it is the degree and length
of the insult that may discriminate between cell survival or death.
In accord with Sozen et al. [159], there seems still to be a gap
between the role of the UPR in CVD in humans and the therapeutic
implications.
As for Nrf2 and CVD, a variety of interventions against Nrf2
induction have been shown to reduce myocardial infarct size in
animals exposed to heart ischemia or I/R injury. Interestingly, H2S
and fumarate have been reported to be cardioprotective
also through the activation of the Nrf2/ARE pathway. Nrf2 may
also be implicated in the cardioprotection offered by ischemic
conditioning.
Finally, the ﬁnding that overexpression of Nrf2 signiﬁcantly
inhibits LVH and cardiac ﬁbrosis is very stimulating, suggesting a
critical role for Nrf2 in maintaining the structural and functional
integrity of the abnormally stressed heart.
Taken together the results of these studies show that Nrf2 ac-
tivation may play a key role in cardioprotection; in this context the
so-called thiol-reactive “indirect antioxidants” [160], a series of
compounds shown to increase Nrf2 activity, have the potential to
open a new scenario in combatting heart ischemia, I/R injuries,
and LVH in the transition to HF.
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